Compare Elastic NV (ESTC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Revvity Inc — how do they compare? Elastic NV trades at $98.23 (market cap $10.00B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Elastic NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Revvity Inc for 12 Days on average.
| ESTC | RVTY | |
|---|---|---|
Market Cap | $10.00B | $16.98B |
Volume | 1,610,337 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $99.91 | $157.36 |
52-Week Low | $43.30 | $82.26 |
Typical Hold Time | 10 Days | 12 Days |
Enterprise Value | $9.14B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $95.26, up 2.32% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches, including a new metrics platform and serverless vector database, highlight innovation in AI and observability. Revenue growth is projected to increase from $1.48B in 2025 to $1.8B in 2026, with net income turning positive to $376M.
The outlook is positive, driven by product momentum and earnings beats, but risks include high valuation multiples and insider selling. The consensus price target of $79.50 suggests caution, though the high target of $120.00 indicates upside potential. Investors should weigh strong fundamentals against valuation concerns and market volatility.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
